Rechercher un essai clinique
Autre(s) option(s) de recherche
32 Résultat(s)
Essai en cours de recrutement = 
; Essai en cours = 
; Essai terminé = 
; Financé par un membre IRDiRC = 
; Membre d'un ERN = 
Essai(s) clinique(s) national(aux)
ALLEMAGNE
Hamburg
HAMBURG
Phase IIa, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and pharmacodynamics of a single dose of Lanreotide PRF in subjects with Acromegaly previously treated and controlled with Octreotide LAR - DE
UKE - Universitätsklinikum Hamburg-Eppendorf
III. Medizinische Klinik und Poliklinik
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS-GHR-LRx, an Antisense Inhibitor of the Growth Hormone Receptor) Administered Once Every 28 Days for 16 Weeks in Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands (SRL) - AT
Institution: Information not provided - AT
AUTRICHE
WIEN
ADDRESS: NOT PROVIDED - AT
Evaluation of a standardized treatment regimen for acromegaly: A multi centre intervention study (phase 4)
Institution: Information not provided - AT
AUTRICHE
WIEN
WIEN
MPOWERED: A Phase 3, Randomized, Active Controlled Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated With Octreotide Capsules vs. Parenteral Somatostatin Receptor Ligands - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Endokrinologie und Stoffwechsel
AUTRICHE
WIEN
WIEN
PATHFNDR-1: A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Acromegaly Treated With Long-acting Somatostatin Receptor Ligands (Phase 3) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Endokrinologie und Stoffwechsel
BELGIQUE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Programme d'extension à long terme du Sorafénib - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment -ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, randomized, double-blind, placebo-controlled, multi-center trial to assess efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly -ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, open-label, single-arm, multi-center trial to assess the long term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly -ES
Institution: Information not provided - ES
ESPAGNE
Madrid
ADDRESS: NOT PROVIDED - ES
PATHFNDR-1: A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Acromegaly Treated With Long-acting Somatostatin Receptor Ligands - ES
Institution: Information not provided - ES
ETATS-UNIS
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Institution: Information not provided - US
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
PAOLA - Etude multicentrique de phase III, randomisée, en groupes parallèles, évaluant l'efficacité et la tolérance du pasiréotide LP 40 mg et 60 mg en double aveugle versus la poursuite d'octréotide LP 30 mg ou de lanréotide Autogel (ATG) 120 mg en ouvert chez des patients ayant une acromégalie insuffisamment contrôlée.
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment-FR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Etude de phase IIIb multicentrique, en ouvert, à bras unique pour évaluer l'éfficacité et la tolérance des pasiréotide chez des patients atteints d'acromégalie et insuffisamment contrôlés avec la première génération d'analogue de la somatostatine.
Institution: Information not provided - FR
FRANCE
ILE-DE-FRANCE
PARIS
ROBOPHYSE : Nouvelle voie d'abord transorale assistée par le robot Da Vinci (Intuitive Surgical) pour la chirurgie des adénomes hypophysaires
Hôpital Fondation Adolphe de Rothschild
Service de Neurochirurgie adulte
FRANCE
NOUVELLE AQUITAINE
PESSAC
Etude de phase IIa, ouverte, de dose croissante, permettant de déterminer la dose maximale tolérée, la sécurité et la tolérance, la pharmacocinétique et la pharmacodynamique d'une dose unique de lanréotide PRF chez des patients atteints d'acromégalie préalablement controllés et traités par l'octréotide LAR.
CHU de Bordeaux-GH Sud - Hôpital Haut-Lévêque
Unité d'Endocrinologie et oncologie endocrinienne
ITALIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma - IT
Institution: Information not provided - IT
ITALIE
LAZIO
ROMA
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
ITALIE
VENETO
VERONA
Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Octreotide LAR-IT
Centro Airett Ricerca e Innovazione - CARI
U.O.C. di Endocrinologia
PAYS-BAS
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
PAYS-BAS
Zuid-Holland
ROTTERDAM
Phase IIa, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and pharmacodynamics of a single dose of Lanreotide PRF in subjects with Acromegaly previously treated and controlled with either Ocreotide LAR or Lanreotide Autogel - NL
Erasmus MC - Erasmus Medisch Centrum
Polikliniek Endocrinologie
SUISSE
Suisse Alémanique
BASEL
Semi-sitting Versus Supine Position in Endoscopic Skull Base Surgery (PosESS-Study) - Study Protocol for a Randomized-controlled Single-blinded Superiority Trial
Universitätsspital Basel
Neurochirurgie
Essai(s) clinique(s) multinational(aux)
AUSTRALIE
Victoria
ADDRESS: NOT PROVIDED - AU
A Phase II Randomised, Open-Label, Parallel Group Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Two Subcutaneous Dosing Regimens of ATL1103 in Adult Patients with Acromegaly
Institution: Information not provided - AU
ETATS-UNIS
Washington
ADDRESS: NOT PROVIDED - US
An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment (Phase IV)
Institution: Information not provided - US
ETATS-UNIS
Washington
ADDRESS: NOT PROVIDED - US
A multi-center, randomized, open-label, phase IV study to investigate the management of pasireotide-induced hyperglycemia with incretin based therapy or insulin in adult patients with cushing's disease or acromegaly.
Institution: Information not provided - US
ETATS-UNIS
Washington
ADDRESS: NOT PROVIDED - US
Efficacy and Safety of Oral Octreolin in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs
Institution: Information not provided - US
ETATS-UNIS
Washington
ADDRESS: NOT PROVIDED - US
A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor) Administered Once Every 28 Days for 16 Weeks in Patients with Acromegaly Being Treated with Long-acting Somatostatin Receptor Ligands (SRL)
Institution: Information not provided - US
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Phase IIa, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and pharmacodynamics of a single dose of Lanreotide PRF in subjects with Acromegaly previously treated and controlled with Octreotide LAR
Institution: Information not provided - FR
FRANCE
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Octreotide LAR
Institution: Information not provided - FR
FRANCE
ILE-DE-FRANCE
BOULOGNE-BILLANCOURT
ITALIE
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Multicenter, Phase II Study to Investigate Efficacy and Safety of ITF2984 in Acromegalic Patients
Institution: Information not provided - IT
SUISSE
Suisse Romande
ADDRESS: NOT PROVIDED - CH